Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market
Mandate

Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market

April 29, 2022 Capital Markets and Public M&A

Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market. The first day of trading is 29 April 2022. In connection with the listing, a shares subscription offer was performed at a subscription price of SEK 16.

Promimic AB is a biomaterials company which produces and markets HAnano Surface, a unique coating for medical implants which strengthens their anchoring in bone tissue. Promimic focuses on the dental and orthopaedic implant market.

Vinge’s team consisted primarily of Anders Strid, Johanna Hamrefält (project manager), Adrian Filipovic, Rebecka Hansson, Anna Högsten and Fredrik Löwenclou.

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024